You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A University of California, Berkeley-led team has drawn a new tree of life that's heavy on bacteria.
In the early stages of the battle over the patent for CRISPR/Cas9, UC and the Broad are each trying to draw up the battleground to suit their strongest arguments.
The study from Bay Area scientists suggests that accounting for the chromosomal structure of DNA could help improve target selection for CRISPR/Cas9 applications.
A California-based research team modified CRISPR/Cas9 to develop a method to track RNA sequences, which they hope will improve disease research.
The University of California, Berkeley, is considering closing its College of Chemistry because of budget woes.
For several reasons, scientists, as well as gene editing therapy company Editas, think that the first clinical trials for CRISPR-based cures will be for hereditary eye diseases.
The researchers say their technique is most effective when used to replace regions of DNA up to 30 base pairs.
In Science this week: how Cas9 identifies its target DNA, and more.
Understanding how the enzyme positions the target DNA for cleavage could lead to new engineered Cas9 variants that increase efficiency and specificity.
The patent office has named the Broad Institute, et al. as the junior party in the proceedings and the University of California, et al. as the senior party.
In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.
National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.
Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.
In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.